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Abstract: Despite remarkable advances in diagnosis and long-term management, asthma 
remains a serious public health concern. Newly updated expert guidelines emphasize the intra- 
and inter-individual variability of asthma and highlight the importance of periodic assessment 
of asthma control. These guidelines update recommendations for step-wise asthma treatment, 
address the burgeoning ﬁ  eld of asthma diagnostics, and stress the importance of a patient and 
health care professional partnership, including written action plans and self monitoring. The ﬁ  eld 
of asthma therapeutics is expanding rapidly, with promising new treatment options available or 
in development that may address some of the existing barriers to successful asthma manage-
ment. These approaches simplify treatment, use combinations of agents in one delivery device
that have complementary actions, or target speciﬁ  c pathways involved in asthma patho-
physiology. Considerable activity is taking place in asthma pharmacogenetics. This review 
provides an overview of these new approaches to managing asthma, including their present 
status and future potential.
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Introduction
The modern age of asthma treatment began more than 50 years ago with the intro-
duction of the ﬁ  rst pressurized metered-dose inhaler (pMDI) in 1956 (Crompton 
2006). The pMDI provided convenient delivery of effective bronchodilator therapy. 
Patients with asthma used the rapidly acting nonselective β-agonists (ie, isoprenaline 
and epinephrine) through the mid 1960s, when the number of asthma-related deaths 
skyrocketed (Crompton 2006). The increased death rate was attributed to a decreased 
response to nonselective β-agonists that prompted patients to overuse their inhalers. 
Reduced sensitivity to bronchodilators became recognized as a harbinger of severe, life-
threatening asthma attacks. Subsequent warnings from regulatory agencies markedly 
reduced the use of the nonselective β-agonists. The selective short-acting β2-adrenergic 
agonist (SABA) salbutamol, called albuterol in the US, replaced the nonselective agents 
(Crompton 2006) and has been demonstrated to be a safe and effective bronchodilator 
(Drazen et al 1996; Dennis et al 2000; NAEPP 2007). During this time, the goal of 
asthma treatment shifted from managing bronchospasm to preventing inﬂ  ammation.
Systemic corticosteroids, long recognized as an effective anti-inﬂ  ammatory treat-
ment for asthma, were associated with serious systemic adverse events when used 
long term (Crompton 2006). Delivery of inhaled corticosteroids (ICSs) via a pMDI 
in the early 1970s ushered in a new era of asthma management (Crompton 2006). 
By the late 1980s and 1990s, the efﬁ  cacy of anti-inﬂ  ammatory therapy using ICSs 
was realized, and ICSs became established as ﬁ  rst-line therapy for patients with 
asthma. However, clinical response to ICS therapy can vary among patients with 
asthma, and the dose-response curve for ICS treatment plateaus for many efﬁ  cacy Therapeutics and Clinical Risk Management 2008:4(2) 364
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measures at low to medium doses (NAEPP 2007); thus, a 
need for new therapies became evident. A novel class of 
asthma therapies was introduced in the 1990s that targeted 
the synthesis or activity of the leukotriene family of inﬂ  am-
matory mediators in the pathogenesis of asthma (Holgate 
et al 1996). Leukotriene modiﬁ  ers (LTMs) generally have 
been shown to be less effective than ICSs (Ducharme and 
Di Salvio 2004), possibly because they target only the 
leukotriene pathway of inﬂ  ammation, whereas ICSs have a 
broader anti-inﬂ  ammatory effect.
Although the selective long-acting β2-adrenergic agonist 
(LABA) salmeterol was introduced as monotherapy in the 
late 1980s and early 1990s, concerns about the risk of severe 
asthma attacks associated with SABAs carried over to this 
class of therapy (Crompton 2006). Moreover, studies dem-
onstrated that monotherapy with a LABA was insufﬁ  cient to 
control asthma (Lazarus et al 2001; Lemanske et al 2001). 
Concerns regarding the safety of high-dose ICSs (eg, rare 
cases of adrenal suppression) and ﬁ  ndings from random-
ized, controlled trials showing a more effective reduction 
in symptoms and exacerbations with a reduced ICS dose 
and a LABA (eg, salmeterol or formoterol) compared with 
high-dose ICS alone eventually cemented the role of LABA 
in the therapeutic armamentarium (Greening et al 1994; 
Pauwels et al 1997; Crompton 2006). Indeed, contemporary 
asthma treatment guidelines recommend add-on LABA to 
ICS therapy for those patients who do not respond optimally 
to low- to medium-dose ICS (Crompton 2006; GINA 2007; 
NAEPP 2007).
Despite these advances in therapy, which have contrib-
uted to declines in asthma morbidity and mortality in the 
US, asthma continues to pose a signiﬁ  cant personal and 
economic burden (ALA 2006; GINA 2007; NAEPP 2007). 
Barriers to improving the burden of asthma are patient vari-
ability and poor patient adherence to therapy. In any given 
patient, the frequency and severity of symptoms, pulmonary 
function, airway hyper-responsiveness, inﬂ  ammation, and 
exacerbations vary over time (GINA 2007; NAEPP 2007). 
Moreover, tremendous inter-patient variability in the natural 
course and treatment response of asthma is attributed to 
the interaction of genetic predisposition, individual patient 
characteristics (eg, obesity, sex, pregnancy), and exposure to 
environmental insults (eg, air pollution, allergens, cigarette 
smoke) (GINA 2007; NAEPP 2007). Asthma is a complex 
disorder with multiple phenotypes and genotypes, which 
contribute to heterogeneity in response to therapy (Szeﬂ  er 
et al 2005; Wechsler and Israel 2005; Hines and McCarver 
2006; GINA 2007; NAEPP 2007). For example, children 
with an allergic phenotype responded better to ICS therapy 
than to LTM therapy (Szeﬂ  er et al 2005). Additionally, it has 
been postulated that differential patient response to therapy 
with LABAs and SABAs is associated with polymorphisms 
in the β2-adrenergic receptor gene; however, results from 
small studies are conﬂ  icting (Hancox et al 1998; Israel et al 
2000; Taylor et al 2000; Dorinsky et al 2004; Israel et al 
2004; Bleecker et al 2006; Wechsler et al 2006; Goldman 
et al 2007). However, two recent large studies demonstrated 
that genotype (n = 2630) did not affect treatment response to 
LABA when administered with ICS (Bleecker et al 2007). 
Although lack of response to ICS therapy also has been 
associated with a speciﬁ  c phenotype and genotype (GINA 
2007), poor adherence can be a cause of therapeutic failure. 
Studies show that overall adherence to ICS therapy is about 
50% (Williams et al 2004; Walders et al 2005). Complex or 
frequent dosing regimens are associated with poor adher-
ence (Claxton 2001; GINA 2007); still, current therapies for 
asthma often require multiple medications delivered more 
than once daily (GINA 2007; NAEPP 2007). Furthermore, 
asthma may be variable in an individual patient; therefore, 
ﬂ  exible treatment strategies that enable a step up or step down 
in treatment to achieve asthma control based on changes in 
symptoms and other facets of the disease are needed (Kips 
2002). In summary, no single treatment approach is appro-
priate for all patients.
Asthma therapeutics is a rapidly evolving ﬁ  eld. Updated 
expert guidelines on the prevention, diagnosis, and manage-
ment of asthma are now available. This paper reviews the new 
guidelines and introduces emerging diagnostic, treatment, 
and monitoring options for asthma.
Recommendations from current 
asthma guidelines
Two recently revised expert guidelines review available data 
and place into perspective the many advances in the pharma-
cologic treatment of asthma achieved over the past decades. 
In the US, the National Asthma Education and Prevention 
Program (NAEPP) of the National Heart, Lung, and Blood 
Institute publishes and periodically updates diagnosis and 
management guidelines aimed at translating basic science and 
clinical research ﬁ  ndings into clinical practice and improving 
patient outcomes. The third edition of the NAEPP guidelines 
was recently released (NAEPP 2007). The most current revi-
sion to the guidelines from the Global Initiative for Asthma 
(GINA) reviews recent data and outlines currently accepted 
strategies for managing asthma from a global perspective 
(GINA 2007).Therapeutics and Clinical Risk Management 2008:4(2) 365
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In the new updates, the NAEPP and GINA guidelines 
now recognize that asthma management is governed by three 
domains: disease severity, control, and response to treatment 
(GINA 2007; NAEPP 2007). Categorization of patients as 
having intermittent, mild persistent, moderate persistent, or 
severe persistent asthma is useful during initial clinical assess-
ments to establish an initial treatment regimen. However, the 
severity of symptoms, lung function assessments, exacerbations, 
and need for SABA typically vary over time. Further, measures 
of disease severity are relatively insensitive predictors of treat-
ment response. Thus, assessment of asthma control, rather than 
disease severity, is now considered the preferred approach for 
routine clinical monitoring and guiding decisions about main-
taining or altering treatment (Table 1) (NAEPP 2007). Asthma 
control should be assessed at 1- to 6-month intervals by the 
health care professional (NAEPP 2007).
Table 1 Assessing asthma control in patients aged 12 years (NAEPP 2007)
Components of control Classiﬁ  cation of asthma control (12 years of age)*
Well controlled Not well controlled Very poorly controlled
Impairment Symptoms 2 days/week 2 days/week Throughout the day
Nighttime awakenings 2×/month 1–3×/week 4×/week
Interference with normal 
activity
None Some limitation Extremely limited
Short-acting β2-adrenergic 
agonist use for symptom 
control (not prevention 
of EIB)
2 days/week 2 days/week Several times per day
FEV1 or peak ﬂ  ow 80% predicted/
personal best
60%–80% predicted/
personal best
60% predicted/
personal best
Validated questionnaires†
 ATAQ 0 1–2 3–4
 ACQ 0.75 1.5 N/A
 ACT 20 16–19 15
Risk Exacerbations 
requiring oral systemic 
corticosteroids‡
0–1 per year 2 per year
Consider severity and interval since last exacerbation
Progressive loss of lung 
function
Evaluation requires long-term follow-up care
Treatment-related adverse 
effects
Medication side effects can vary in intensity from none to very troublesome/worrisome. 
The level of intensity does not correlate to speciﬁ  c levels of control, but should be 
considered in the overall assessment of risk.
Recommended
action for treatment 
(see Figure 1)
•  Maintain current step
•   Regular follow-ups every 
1–6 months to maintain 
control
•   Consider step-down if 
well controlled for at 
least 3 months
• Step  up§ 1 step
•  Re-evaluate in 2–6 weeks
•   For side effects, consider 
alternative treatment 
options
•   Consider short course
of systemic oral 
corticosteroids
• Step  up§ 1–2 steps
•  Re-evaluate in 2 weeks
•   For side effects, consider 
alternative treatment 
options
*The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. The level of control is based on the most severe 
impairment or risk category.  Assess impairment domain by patient’s recall of previous 2–4 weeks and by spirometry/or peak ﬂ  ow measures. Symptom assessment for longer 
periods should reﬂ  ect a global assessment, such as inquiring whether the patient’s asthma is better or worse since the last visit.
†Validated questionnaires for the impairment domain (the questionnaires do not access assess lung function or the risk domain). Minimal important difference: 1.0 for the ATAQ; 
0.5 for the ACQ; not determined for the   ACT.  ACQ values 0.76–1.4 are indeterminate regarding well-controlled asthma.
‡At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations 
(eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had 2 exacerbations requiring 
oral systemic corticosteroids in the past year may be considered the same as patients who have not–well-controlled asthma, even in the absence of impairment levels consistent 
with not–well-controlled asthma.
§Before step-up in therapy, review adherence, environmental control, and comorbid conditions. If an alternative treatment option was used in a step, discontinue and use the 
preferred treatment for the step.
Abbreviations: EIB, exercise-induced bronchospasm; FEV1, forced expiratory volume in 1 second;   ATAQ,  Asthma Therapy Assessment Questionnaire©;   ACQ,   Asthma Control 
Questionnaire©;   ACT,   Asthma Control Test™; ICU, intensive care unit; N/A, not available. Therapeutics and Clinical Risk Management 2008:4(2) 366
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No cure exists for asthma; however, the use of optimally 
effective treatment regimens can achieve control (GINA 
2007). Asthma control embodies the dual concepts of mini-
mizing impairment and reducing risk for deterioration and 
exacerbations (NAEPP 2007). This new emphasis on regular 
assessment of asthma control is a key paradigm shift in the 
updated NAEPP and GINA guidelines. Both sets of guide-
lines focus on the importance of forming a patient  – clinician 
alliance to foster long-term treatment adherence and achieve 
optimal asthma control. These guidelines also advocate 
patient education, the use of guided self-management, 
and the individualization of treatment plans (GINA 2007; 
NAEPP 2007). The educational process begins at diagnosis 
and continues throughout follow-up care, with the patient (or 
caregiver in the case of children) and health care provider 
working together to develop goals and a personalized, written 
self-management plan. These plans include guidelines for 
patient-guided adjustment of medications when needed for 
deteriorating asthma control or exacerbations.
The NAEPP and GINA guidelines discuss the place 
of available pharmacologic treatments in asthma therapy, 
categorizing them as drugs used for long-term control or 
immediate relief of acute symptoms and exacerbations 
(GINA 2007; NAEPP 2007). In all age groups and asthma 
severity levels, SABAs (NAEPP or GINA) and the LABA 
formoterol (GINA only) are considered the agents of choice 
for rapid relief of bronchoconstriction or for prevention of 
exercise-induced asthma. In Europe, formoterol is the only 
LABA indicated for rapid relief of bronchoconstriction; it 
is to be used as a reliever only in patients being treated with 
an ICS. The need for higher or more frequent SABA or 
LABA doses suggests deteriorating asthma control and is an 
indication for medical attention and increased therapy. Step-
wise pharmacologic management algorithms for controller 
therapy are available in both guidelines; the NAEPP has a 
new 6-step approach, while GINA has revised their 5-step 
approach. The NAEPP algorithm for adults and adolescents 
aged 12 years or older is shown in Figure 1.
OR
Figure 1 Asthma management approach based on control for adults and adolescents 12 years of age and older.
Abbreviations: EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; PRN, pro re nata
(as needed); SABA, short-acting β2-adrenergic agonist.Therapeutics and Clinical Risk Management 2008:4(2) 367
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In both sets of guidelines, low-dose ICSs remain ﬁ  rst-line 
therapy for control of persistent asthma in adults and older 
children (Figure 1) because of their potent anti-inﬂ  ammatory 
effects and effectiveness compared with other therapies 
(GINA 2007; NAEPP 2007). Several ICSs are on the market, 
each with a unique bioavailability and potency proﬁ  le. 
Although studies of equipotent doses are imperfect (Selroos 
2007), the GINA and NAEPP guidelines provide estimated 
dose ranges for low-dose, medium-dose, and high-dose 
ICS therapy based on published comparative clinical trials 
and dose-ranging studies. For example, the NAEPP daily 
low-dose range is 180–600 µg for budesonide (BUD) DPI 
and 100–300 µg for ﬂ  uticasone (FP) DPI (NAEPP 2007), 
whereas the GINA daily low-dose range is 200–400 µg for 
BUD and 100–250 µg for FP (GINA 2007). A low dose of 
an ICS is preferred step 2 therapy; however, monotherapy 
with a leukotriene receptor antagonist (LTRA) (montelukast, 
zaﬁ  rlukast) or synthesis inhibitor (zileuton; GINA only) also 
is a recommended alternative treatment for patients aged 
5 years or older. Montelukast also is recommended by the 
NAEPP for patients aged 0–4 years (GINA 2007; NAEPP 
2007). Only the NAEPP guidelines recommend additional 
alternative choices for step 2 monotherapy – cromolyn (all 
ages), nedocromil (5 years), and theophylline (5 years). 
Monotherapy with a LABA is not recommended in either 
set of guidelines.
Guideline recommendations for patients who do not 
respond to low-dose ICS therapy (step 2) differ slightly 
between GINA and NAEPP (Figure 1) (GINA 2007; 
NAEPP 2007). In GINA, combination therapy with a low-
dose ICS, and a LABA is the preferred next-step treatment 
for patients aged older than 5 years. In NAEPP, either this 
combination or a medium-dose ICS are preferred therapy for 
patients 12 years of age or older (step 3). For patients aged 
5–11 years, the NAEPP gives equal preference to treatment 
with medium-dose ICS or low-dose ICS plus a LABA, 
LTRA, or theophylline (step 3). For patients whose asthma 
is not controlled on step 3 therapy, both sets of guidelines 
list medium- or high-dose ICS plus a LABA (steps 4 and 5 
NAEPP, respectively; step 4 GINA) as preferred therapy. 
Notably, the ﬁ  xed-dose combination ICS/LABA inhaler 
BUD/formoterol (FM) DPI is approved for use as mainten-
ance and reliever therapy in Europe (Rabe et al 2006; Kuna 
et al 2007), but is approved only for maintenance use in the 
US. Combination therapy with a medium-dose ICS plus a 
LTRA, zileuton (NAEPP 12 years; GINA 5 years), or 
sustained-release theophylline are additional options for 
GINA and NAEPP step 4 therapy. The addition of oral 
corticosteroids to ICS plus LABA combination therapy is 
the preferred last step of GINA (step 5) and NAEPP (step 
6) therapy. Anti-immunoglobulin E (IgE) treatment (omali-
zumab) also can be added for patients with allergies who do 
not respond to conventional therapy.
Finally, studies of asthma treatment in young children 
are limited; therefore, treatment recommendations are 
different for young children than for adults and older 
children (GINA 2007; NAEPP 2007). Evidence supports 
the use of ICS as the GINA- and NAEPP-preferred daily 
controller for infants and young children. The GINA and 
NAEPP recommend medium-dose ICS as the next-step 
treatment for children younger than 5 years whose asthma 
is not well controlled on low-dose ICS alone (GINA 2007; 
NAEPP 2007).
New tools and parameters for 
asthma diagnosis and monitoring
Routine, objective assessment of lung function is necessary 
to monitor asthma control and evaluate response to treatment. 
Spirometry, particularly a patient’s forced expiratory volume 
in 1 second (FEV1), and peak expiratory ﬂ  ow (PEF) monitoring 
remain the cornerstones of noninvasive asthma assessment tools 
available to health care professionals (GINA 2007; NAEPP 
2007). The GINA and NAEPP guidelines acknowledge the 
emerging research on these techniques. For instance, the 
NAEPP has added a recommendation to use the FEV1/forced 
vital capacity ratio to classify asthma severity in children older 
than 4 years because of its sensitivity. Nonetheless, existing 
pulmonary function tests are effort dependent, requiring some 
degree of coordination on the part of the patient, and may be 
impractical for use in young children (GINA 2007).
Impulse oscillometry is a particularly useful measure of 
lung function in young children because it requires only pas-
sive cooperation (Marotta et al 2003). The patient breathes 
normally into a mouthpiece for a short period while a pulse-
shaped pressure ﬂ  ow excitation is delivered to the respiratory 
system by a loudspeaker. Resistance and reactance of the 
pulse by the child’s respiratory system provides a measure 
of lung function. Impulse oscillometry has been shown to 
detect lung function abnormalities in young children at 
increased risk of persistent asthma, particularly those with 
atopic disease. In addition to new diagnostic and monitoring 
methods for lung function, development of new, accurate, and 
noninvasive tests to assess asthma control and exacerbation 
risk is proceeding at a rapid pace.
Measurement of biomarkers of lung inﬂ  ammation is used 
in clinical research, and several techniques hold promise Therapeutics and Clinical Risk Management 2008:4(2) 368
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for future use in routine clinical practice. Nitric oxide (NO) 
is one mediator of inﬂ  ammation. Clinically, the fractional 
concentration of exhaled NO (FeNO) distinguishes a patient 
with asthma not receiving anti-inﬂ  ammatory treatment, 
correlates with other markers of disease severity and inﬂ  am-
mation, and, in some studies, predicts responsiveness to cor-
ticosteroid therapy (ATS 2006; NAEPP 2007). An analyzer 
of FeNO is commercially available and has been approved 
for use in the US (NIOX® Flex, Aerocrine Inc., New York, 
USA) (Silkoff et al 2004; Alving et al 2006), but cost and 
reimbursement challenges have hindered widespread clini-
cal use (ATS 2006). Another FeNO monitor that utilizes a 
biosensor platform and patented Sol-Gel technology is under 
development (Apieron Inc., Menlo Park, CA, USA). Eosino-
phils are important effector cells, and elevated levels in the 
sputum and peripheral blood are another well-recognized 
marker of inﬂ  ammation in asthma. Measurement of sputum 
eosinophilia represents a possible tool for adjusting asthma 
therapy to reduce exacerbations in adult patients (Petsky 
et al 2007). However, standardization of methodology and 
the complexity of the measurement process currently limit 
the usefulness of this technique (NAEPP 2007). Finally, 
increased levels of IgE are present in patients with allergic 
airway inﬂ  ammation. Children with elevated serum IgE 
levels have responded positively to ICS treatment, suggest-
ing that this biomarker may be useful for guiding treatment 
decisions (Szeﬂ  er et al 2005).
In summary, while the GINA and NAEPP guidelines rec-
ognize the potential usefulness of measuring FeNO, sputum 
eosinophils, and serum IgE, both fall short of recommending 
the widespread use of these and other biomarkers until further 
prospective, randomized, controlled studies in adults and 
children are conducted (GINA 2007; NAEPP 2007).
Treatment update
Monotherapy with an ICS
ICSs are the ﬁ  rst line of therapy for control of persistent asthma 
in adults and older children and considered the most effective 
anti-inﬂ  ammatory treatment (GINA 2007; NAEPP 2007). A 
dry powder formulation of mometasone furoate (Asmanex® 
Twisthaler 220 µg, Schering Corporation, Kenilworth, NJ, 
USA) was approved in 2005 in the US for the maintenance 
treatment of asthma in patients 12 years of age or older 
(Asmanex® PI). In addition, a new dry powder formulation 
of BUD (Pulmicort Flexhaler™ 90 µg, 180 µg; AstraZeneca, 
Wilmington, DE, USA) was recently approved in the US for 
maintenance treatment of asthma in adult and pediatric patients 
6 years of age or older (Pulmicort Flexhaler PI). The new 
product has an indicator window that enables the patient to see 
approximately how many doses remain in the canister.
Monotherapy or add-on therapy
with a leukotriene modiﬁ  er
Leukotriene modiﬁ  ers include two types of agents, the 
LTRAs, which are antagonists of cysteinyl leukotriene 1 
(eg, montelukast [Singulair®; Merck and Co., Inc., West 
Point, PA, USA], zaﬁ  rlukast [Accolate®; AstraZeneca LP; 
Wilmington, DE, USA]), and agents that block the synthesis 
of 5-lipoxygenase from arachidonic acid (zileuton [Zyﬂ  o®; 
Critical Therapeutics Inc, Lexington, MA, USA]). Although 
a new formulation was launched in 2005, zileuton has been 
available since 1997 as a 600-mg oral tablet that is adminis-
tered four times daily in adults and children aged older than 
12 years. A sustained-release formulation was approved for 
twice-daily administration in May 2007. Hepatic toxicity 
can occur during zileuton therapy (Wenzel 1998; Lazarus 
et al 1998). Therefore, pretreatment baseline and periodic 
monitoring of hepatic enzymes is recommended, particularly 
during treatment initiation (Wenzel 1998).
Sin et al conducted a systematic review and meta-analysis 
of therapies used in persistent asthma and concluded that the 
LTMs (including LTRAs and zileuton) were more effective 
than placebo in preventing asthma exacerbations, but less 
effective than ICS (Sin et al 2004). Indeed, the GINA guide-
lines consider zileuton to be an alternative, but not preferred, 
monotherapy for step 2 treatment; the NAEPP and GINA 
guidelines consider zileuton an alternative add-on therapy 
for step-up (3 or 4) care for adults and adolescents (Figure 1) 
(GINA 2007; NAEPP 2007). In patients with aspirin-intoler-
ant asthma, addition of zileuton to usual ICS or oral corticoste-
roid therapy was associated with improvements in pulmonary 
function, and symptoms of rhinosinusitis and asthma (Dahlén 
et al 1998). A similarly designed study using montelukast 
was associated with similar beneﬁ  ts in patients with aspirin-
intolerant asthma (Dahlén et al 2002). Taken together, these 
studies show the important role of the leukotriene pathway 
in this disorder. In summary, zileuton may be an appropri-
ate alternative treatment option as monotherapy for patients 
with mild persistent asthma, particularly those with a distinct 
asthma phenotype, and as an add-on therapy for patients with 
moderate or severe persistent asthma.
ICS/LABA combination therapy
The ICSs are considered the most effective anti-inﬂ  ammatory 
treatment for control of persistent asthma, and inhaled 
β2-adrenergic agonists are the most effective bronchodilators Therapeutics and Clinical Risk Management 2008:4(2) 369
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(Barnes 2002; NAEPP 2007). The ICSs inhibit eosinophils, 
macrophages, T-lymphocytes, mast cells, and other markers 
of inﬂ  ammation. LABAs may possess anti-inﬂ  ammatory 
properties or other beneﬁ  cial pharmacologic effects that 
complement ICSs, such as inhibiting the release of inﬂ  am-
matory mediators from mast cells, blocking plasma exu-
dates and reducing airway edema, and modulating airway 
sensory nerves that mediate airway hyper-responsiveness 
(Figure 2).
A Cochrane database systematic review of 30 random-
ized, controlled studies demonstrated that the addition of a 
LABA to ICS therapy was more effective than higher dose 
ICS monotherapy in preventing treatment discontinuations 
because of deteriorating asthma control in patients with 
primarily moderate disease (Greenstone et al 2005). An 
additional Cochrane review of 10 trials in adults with asthma 
maintained on moderate to high ICS doses demonstrated 
that LABA addition enabled an ICS dose reduction with 
improved or maintained asthma control (Gibson et al 2005). 
Combined therapy with low-dose ICS and LABA currently 
is used extensively for treatment of persistent asthma in the 
US and Europe.
Recognition of the efficacy and widespread use of 
combination therapy led to the development of ﬁ  xed-dose 
combination inhalers (Barnes 2002; Miller-Larsson and 
Selroos 2006). Two ICS/LABA combinations currently 
are available as ﬁ  xed-dose proprietary formulations. Fluti-
casone propionate and salmeterol (FP/SAL) is available as 
a DPI (Advair Diskus® 100/50 µg, 250/50 µg, 500/50 µg; 
GlaxoSmithKline, Research Triangle Park, NC, USA; 
Seretide Diskus®; GlaxoSmithKline, Middlesex, UK) and 
recently as a pMDI (Advair hydrofluoroalkane [HFA] 
45/21 µg, 115/21 µg, 230/21 µg; GlaxoSmithKline, Research 
Triangle Park, NC, USA). The FP/SAL HFA pMDI formula-
tion demonstrated greater improvements in asthma control 
compared with the individual monocomponents (Pearlman 
et al 2004; Nathan et al 2006). The FP/SAL HFA pMDI at 
the initial formulation dosage of 50/25 µg × 2 inhalations 
twice daily demonstrated similar efﬁ  cacy and tolerability as 
FP/SAL DPI 100/50 µg × 1 inhalation once daily (Bateman 
et al 2001).
In 2000, BUD and FM in one inhaler (BUD/FM) 
became available outside of the US as a DPI (Symbicort 
Turbuhaler®; AstraZeneca, Lund, Sweden). In June 2007, 
a pMDI formulation of BUD/FM became available in the 
US (Symbicort inhalation aerosol 80/4.5 µg or 160/4.5 µg; 
AstraZeneca LP, Wilmington, DE, USA). Therapeutic 
equivalence and similar tolerability has been demonstrated 
for BUD/FM administered via DPI or pMDI in patients with 
asthma (Morice et al 2006; Morice et al 2007a; Morice et al 
2007b). In patients with moderate to severe persistent asthma 
previously receiving ICS therapy, BUD/FM administered 
together via a pMDI demonstrated similar asthma control 
as BUD pMDI plus FM DPI administered together via 
separate inhalers. The therapy also provided signiﬁ  cantly 
greater asthma control compared with BUD pMDI alone or 
Inhaled
corticosteroids
Figure 2 Complementary effects of the long-acting β2-adrenergic agonists (LABA) and inhaled corticosteroids on the pathophysiologic events underlying asthma. Reproduced 
with permission from Barnes PJ. 2002. Scientiﬁ  c rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J, 19:182–91. Copyright 
2002 © European Respiratory Society Journals Ltd.Therapeutics and Clinical Risk Management 2008:4(2) 370
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FM DPI alone (Noonan et al 2006). Additionally, BUD/FM 
pMDI demonstrated significantly increased pulmonary 
function versus its monocomponents in patients with mild 
to moderate persistent asthma previously treated with ICSs 
(Corren et al 2007).
The proprietary formulations of BUD/FM and FP/SAL 
are available as ﬁ  xed doses of the LABA component, with 
different dose levels of the ICS component, which is useful 
for patients needing to adjust the dose of corticosteroid. A 
randomized, controlled study demonstrated that patients 
stabilized on a high dose of BUD alone could step down to 
low-dose therapy without loss of symptom or lung function 
control (Foresi et al 2000). Furthermore, this study showed 
that use of a high dose of BUD at the onset of an exacerba-
tion was associated with additional clinical beneﬁ  t. Another 
randomized study showed that as-needed use of FM increased 
the time to the ﬁ  rst severe asthma exacerbation compared 
with standard rescue therapy (Tattersﬁ  eld et al 2001).
These ﬁ  ndings prompted studies to assess whether the 
BUD/FM combination inhaler was beneﬁ  cial when used both 
as regular maintenance therapy and as-needed reliever therapy 
for patients needing additional asthma control (O’Byrne et al 
2005; Vogelmeier et al 2005; Rabe et al 2006; Bousquet et al 
2007; Kuna et al 2007). Maintenance and as-needed reliever 
therapy is possible with the BUD/FM combination inhaler 
because FM has an onset of bronchodilator action within 
the ﬁ  rst minute (van der Woude et al 2004) with a similar 
efﬁ  cacy and safety to salbutamol in patients with asthma 
(Pauwels et al 2003; Balanag et al 2006). The contributions of 
BUD and FM administered as needed were demonstrated in 
a study in which patients received BUD/FM (160/4.5 µg × 1 
inhalation twice daily) as maintenance therapy plus either 
terbutaline (0.4 mg), FM (4.5 µg), or BUD/FM (160/4.5 µg) 
for as-needed rescue medication (Rabe et al 2006). Patients 
who used as-needed BUD/FM had a signiﬁ  cantly longer time 
to the ﬁ  rst severe exacerbation and a signiﬁ  cantly lower rate 
of severe exacerbations versus patients who used as-needed 
FM or terbutaline. As-needed FM also signiﬁ  cantly increased 
the time to the ﬁ  rst severe exacerbation and reduced the rate 
of severe exacerbations versus as-needed terbutaline.
In a study evaluating BUD/FM as maintenance and 
reliever therapy, maintenance treatment with ﬁ  xed-dose 
BUD/FM DPI 80/4.5 µg (administered as 1 inhalation twice 
daily) or BUD 320 µg (administered as 1 inhalation twice 
daily), both with as-needed SABA, was compared with 
maintenance BUD/FM 80/4.5 µg twice daily plus additional 
inhalations as needed (O’Byrne et al 2005). The BUD/FM 
maintenance plus reliever regimen resulted in signiﬁ  cantly 
improved symptom control, pulmonary function, and reduced 
rates of severe exacerbations and related complications 
(Figure 3) than either of the fixed-dose plus as-needed 
SABA regimens (O’Byrne et al 2005). Another study further 
demonstrated that maintenance and reliever treatment with 
BUD/FM (160/4.5 µg × 2 inhalations twice daily then 
titrated, plus additional inhalations as needed) provided 
similar improvements in pulmonary function with a reduced 
risk of exacerbations when compared with titrated ﬁ  xed-
dose FP/SAL (250/50 µg twice daily then titrated) plus as-
needed SABA (Vogelmeier et al 2005). Kuna et al (2007) 
demonstrated that treatment with BUD/FM, when used as 
both maintenance (160/4.5 µg × 1 inhalation twice daily) and 
reliever therapy, signiﬁ  cantly increased the time to the ﬁ  rst 
severe exacerbation, reduced the rate of severe exacerbations, 
and reduced the overall ICS dose compared with treatment 
with higher doses of ﬁ  xed-dose FP/SAL (125/25 µg × 2 
inhalations twice daily) or ﬁ  xed-dose BUD/FM (320/9 µg × 1 
inhalation twice daily) plus as-needed SABA. Improvements 
in pulmonary function and asthma symptom-control measures 
were similar among treatments.
In addition, a recent study compared the efﬁ  cacy of 
BUD/FM as maintenance and reliever therapy (160/4.5 µg × 2 
inhalations twice daily plus as-needed inhalations) with 
sustained high-dose FP/SAL (500/50 µg twice daily plus 
SABA) for 6 months in patients with uncontrolled asthma 
(Bousquet et al 2007). BUD/FM as maintenance and reliever 
therapy signiﬁ  cantly reduced the number of total exacerba-
tions and exacerbations requiring hospitalizations/emergency 
department treatment with signiﬁ  cantly less ICS exposure 
compared with sustained high-dose FP/SAL plus SABA. No 
differences in the time to the ﬁ  rst severe exacerbation, pul-
monary function, or asthma symptoms between treatments, 
however, were observed (Bousquet et al 2007).
In the US, the Food and Drug Administration (FDA) has 
required “black box” warnings in the prescribing information 
for all LABA products, including FP/SAL and BUD/FM 
combination therapy. It is recommended that LABAs only 
be used in patients with asthma not adequately controlled on 
other asthma controller medication (eg, low- to medium-dose 
ICSs). This safety warning is based on a large (N = 26,355), 
placebo-controlled trial, which demonstrated that treatment 
with SAL pMDI 42 µg twice daily (Serevent®; Glaxo Well-
come, Middlesex, UK) resulted in an increase in asthma-
related deaths compared with placebo (13/13,176 patients 
and 3/13,179 patients, respectively) (Nelson et al 2006). 
A retrospective evaluation of these data suggested that the 
increased risk of asthma-related death was primarily in Therapeutics and Clinical Risk Management 2008:4(2) 371
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those who reported using a LABA but not an ICS, at baseline 
(Nelson 2006). Moreover, a recent review of 69 trials of 
patients treated with FM (n = 50,549; 94% prescribed ICS) 
showed that FM was not associated with increased asthma-
related deaths or serious adverse events (Sears et al 2007). 
These studies, as well as earlier LABA data showing a lack 
of anti-inﬂ  ammatory properties and a lack of efﬁ  cacy as 
monotherapy (Nelson 2006), support that LABAs should 
be administered in combination with an ICS as recom-
mended in the NAEPP and GINA guidelines (GINA 2007; 
NAEPP 2007).
In summary, ﬁ  xed-dose combinations of ICS/LABA 
have recently become the standard of care for patients who 
are symptomatic on ICS monotherapy. Emerging research 
suggests additional clinical beneﬁ  t for BUD/FM maintenance 
and reliever therapy. Use of BUD/FM as both rescue and 
maintenance therapy has gained acceptance outside of the US 
(GINA 2007), where the BUD/FM DPI has been available 
for more than 6 years.
Anti-IgE therapy
Omalizumab (Xolair®; Genentech Inc, San Francisco, CA, 
USA) is a relatively new addition to the asthma treatment 
armamentarium. This agent is a humanized monoclonal 
antibody that binds to the Fc portion of circulating IgE anti-
body on mast cells and basophils, desensitizing mast cells 
to allergens. The mast cell–stabilizing effect of omalizumab 
blocks the release of inﬂ  ammatory mediators in the lung and 
reduces IgE levels in response to allergen exposure (Chang 
and Shiung 2006; Corry and Kheradmand 2006; Strunk and 
Bloomberg 2006).
The guidelines recommend consideration of adjunctive 
omalizumab treatment at steps 5 or 6 of care for patients at 
least 12 years of age who have allergies and severe persistent 
asthma not controlled on high-dose ICS/LABA therapy (GINA 
2007; NAEPP 2007). Findings from placebo-controlled 
trials in adults, adolescents, or children with moderate to 
severe persistent asthma demonstrate that the addition of 
subcutaneously administered omalizumab to an existing 
regimen of high-dose ICS reduced the rate of exacerbations 
and enabled ICS dose reductions (Busse et al 2001; Milgrom 
et al 2001; Solèr et al 2001; Humbert et al 2005). In another 
placebo-controlled study of patients with severe asthma, 
omalizumab was not associated with a statistically signiﬁ  cant 
reduction in the exacerbation rate (mean number of asthma 
exacerbations per patient in the corticosteroid-reduction 
Figure 3 Reduced rates of severe asthma exacerbations and exacerbation subtypes associated with budesonide/formoterol maintenance plus reliever therapy (BUD/FM 
maintenance + relief) compared with a ﬁ  xed-dose regimen of either BUD/FM plus a short-acting β2-adrenergic agonist (BUD/FM + SABA) or budesonide monotherapy plus 
a SABA (BUD + SABA). Reproduced with permission from O’Byrne PM, Bisgaard H, Godard PP, et al. 2005. Budesonide/formoterol combination therapy as both maintenance 
and reliever medication in asthma. Am J Respir Crit Care Med, 171:129–36. Copyright 2005 © American Thoracic Society.
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phase: placebo 0.34, omalizumab 0.19), but the ICS doses 
needed to achieve control were signiﬁ  cantly reduced (Holgate 
et al 2004).
In summary, treatment with omalizumab generally is 
reserved for patients unresponsive to standard ICS therapy 
who have documented allergic asthma and a serum IgE level 
between 30 IU and 700 IU (Marcus 2006). Omalizumab 
is a considerably more costly treatment than other avail-
able asthma treatments, ranging in price from US$6,000 to 
US$37,000 per year (Marcus 2006). More widespread use 
of omalizumab will likely not occur until cost-effectiveness 
studies demonstrate meaningful cost avoidance (Miller and 
Reeves 2005; Marcus 2006).
Future treatments
Adherence to long-term therapy is an important consideration 
in the treatment of any chronic disease, and asthma is no 
exception. A meta-analysis of 76 heterogeneous studies that 
included electronic monitoring data on medication adherence 
demonstrated an inverse linear relationship between dosing 
frequency and rates of adherence (Claxton et al 2001). The 
need to simplify therapy and improve medication adherence 
has fostered the search for novel means of administering 
existing therapies. Research on new molecular entities with 
improved pharmacokinetic proﬁ  les compared with current 
medications within existing therapeutic classes is one focus 
of recent drug development. Another important focus of 
ongoing drug development efforts revolves around ﬁ  nding 
therapies that target speciﬁ  c events in the inﬂ  ammatory 
pathway.
ICS monotherapy
Ciclesonide (Alvesco®; ALTANA Pharma AG, Bad 
Homburg v.d.H. Germany), a novel corticosteroid pro-
drug that can be administered on a once-daily dosing 
schedule, has no intrinsic anti-inﬂ  ammatory properties. 
After inhalation, ciclesonide is hydrolyzed in the lung to 
the pharmacologically active metabolite desisobutyryl-
ciclesonide (Nave 2006). Commercially available in Europe 
since 2005, ciclesonide is currently under evaluation by 
the US FDA. Findings from 2 randomized, double-blind, 
12-week, placebo-controlled trials in patients with mild to 
moderate persistent asthma demonstrated that ciclesonide 
doses of 80, 160, and 320 µg once daily signiﬁ  cantly 
improved pulmonary function and asthma symptoms and 
reduced albuterol use compared with placebo (Pearlman 
et al 2005). A systematic review of limited comparative 
phase 2 studies concluded that ciclesonide was as effective 
as BUD or FP, but the available studies were not sufﬁ  cient 
to determine whether ciclesonide was less likely to sup-
press hypothalamic-pituitary-adrenal axis function (Dyer 
et al 2006). In recent noninferiority studies of patients with 
mild to moderate asthma, ciclesonide 320 µg once daily 
was similar to twice-daily BUD 200 µg or FP 200 µg in 
improving pulmonary function, controlling asthma symp-
toms, and reducing the need for rescue bronchodilators 
(Hansel et al 2006; Boulet et al 2007). The only apparent 
differences among the ICSs in their adverse event proﬁ  les 
was a signiﬁ  cantly higher frequency of oral candidiasis with 
FP versus ciclesonide (9 vs 0 cases) (Boulet et al 2007) 
and a signiﬁ  cant decrease from baseline in urinary cortisol 
concentrations for BUD (400 µg/day) versus ciclesonide 
(Hansel et al 2006). Further long-term studies are still 
needed to determine if any clinically relevant long-term 
efﬁ  cacy or safety advantages exist. A novel submicron 
particle suspension of BUD for nebulization (Unit Dose 
Budesonide [UDB]; MAP Pharmaceuticals Inc., Mountain 
View, CA) recently has been developed for the treatment 
of asthma. A randomized, double-blind, active-controlled, 
single-dose, crossover study in healthy volunteers (n = 16) 
evaluated the pharmacokinetics and safety of UDB admin-
istered at three different strengths (0.06 mg, 0.12 mg, and 
0.24 mg/2 mL) versus budesonide inhalation suspension 
(BIS) 0.25 mg/2 mL (Pulmicort Respules®; AstraZeneca, 
Wilmington, DE, USA). UDB was well tolerated in healthy 
adults. UDB 0.24 mg had a signiﬁ  cantly greater Cmax com-
pared with BIS 0.25 mg. In addition, Tmax was signiﬁ  cantly 
greater for all three doses of UDB compared with BIS. Thus, 
UDB is absorbed more rapidly than BIS (Bosco et al 2007). 
The clinical signiﬁ  cance of this ﬁ  nding is unknown; larger 
clinical trials in adults and pediatric patients with asthma 
have not been reported.
Combination ICS/LABA therapy
The focus of future development for ICS/LABA therapy is on 
once-daily dosing with a 24-hour LABA and a LABA with 
a rapid onset. In the US, the currently available ﬁ  xed-dose 
ICS/LABA inhalers are approved for administration twice 
daily. Although the ICSs BUD and mometasone have shown 
efﬁ  cacy when administered once daily, currently available 
LABAs are usually administered twice daily (NAEPP 2007). 
Once-daily administration of BUD/FM DPI was investigated 
in a double-blind, active-control study in 523 patients whose 
asthma was not fully controlled on ICS alone (Buhl et al 
2003). This study compared once-daily dosing of BUD/
FM 160/4.5 µg × 2 inhalations with twice-daily dosing of Therapeutics and Clinical Risk Management 2008:4(2) 373
New approaches to managing asthma: a US perspective
BUD/FM 160/4.5 µg × 1 inhalation or once-daily dosing of 
BUD 400 µg  ×  1 inhalation. Each treatment resulted in the 
same total daily dose of budesonide or formoterol. Compared 
with BUD alone, the ﬁ  xed-dose combination of ICS/LABA 
resulted in signiﬁ  cant improvements in pulmonary function 
(Figure 4), asthma symptoms, and days free from asthma 
symptoms or rescue SABA regardless of dosing schedule. 
No signiﬁ  cant differences in asthma control days were 
observed between the once-daily and twice-daily BUD/FM 
dosage groups.
Other ICS/LABA combinations are being evaluated for 
administration from one single inhaler. For example, a ﬁ  xed-
dose combination inhaler of ciclesonide and FM is currently 
in phase 2 clinical trial evaluation for twice-daily adminis-
tration (ClinicalTrials.gov 2007a). In addition, twice-daily 
dosing of a mometasone/FM combination inhaler (Schering-
Plough) is in phase 3 clinical trials (ClinicalTrials.gov 
2007b). Several phase III clinical trials of ﬂ  uticasone/FM 
pMDI (FlutiFormTM; SkyePharma/Abbott) are recruiting 
pediatric and adult patients with mild, moderate, and severe 
asthma (ClinicalTrials.gov 2007c). Although mometasone 
is a marketed ICS, indacaterol is a new LABA that has 
demonstrated sustained 24-hour bronchodilation (Beeh et al 
2007). A once-daily ﬁ  xed-dose ICS/LABA combination 
inhaler of mometasone/indacaterol is under development 
using the Twisthaler® inhalation device (Schering-Plough 
Corporation 2006).
Immunotherapy
Immunotherapies target speciﬁ  c elements of asthma patho-
physiology. Several different immunotherapeutic approaches 
are being investigated for the treatment of asthma. Current 
research includes agents used to treat either atopic or inﬂ  am-
matory disease states (eg, rheumatoid arthritis).
The role of allergen-speciﬁ  c immunotherapy in the treat-
ment of asthma has been extensively studied. A systematic 
review of 75 trials demonstrated that allergen-speciﬁ  c 
intradermal or subcutaneous immunotherapy (SCIT) for 
asthma reduced asthma symptoms and medication use 
and improved bronchial hyper-reactivity (Abramson et al 
2003). Moreover, a recent long-term trial demonstrated that 
a 3-year course of SCIT given to children and adolescents 
with grass and/or birch pollen allergy resulted in clinical 
beneﬁ  t and possible prevention of the development of 
asthma 7 years after therapy (Jacobsen et al 2007). The 
new NAEPP guidelines recommend consideration of 
SCIT at steps 2 to 4 for patients aged 5 years and older 
who have allergic asthma (NAEPP 2007). However, the 
Figure 4 Daily change in mean morning peak expiratory ﬂ  ow (PEF) achieved with once-daily budesonide/formoterol (160/4.5 µg; two inhalations), twice-daily budesonide/
formoterol (160/4.5 µg; one inhalation), or once-daily budesonide (400 µg). Reproduced with permission from Buhl R, Creemers JP, Vondra V, et al. 2003. Once-daily budesonide/
formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med, 97:323–30. Copyright © 2003 Elsevier Ltd.
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GINA guidelines state that speciﬁ  c immunotherapy only be 
considered if strict environmental avoidance and pharma-
cologic intervention have been unsuccessful at controlling 
the patient’s asthma (GINA 2007).
Sublingual immunotherapy (SLIT) is being considered 
as a possible alternative to the subcutaneous route of admin-
istration (Passalacqua et al 2004). Although it is gaining 
acceptance for treatment of atopic disorders, such as allergic 
rhinitis, SLIT of allergen extracts represents a new and novel 
treatment for children with allergic asthma (Sopo et al 2004). 
In a systematic review of SLIT using house dust mite, olive 
pollen, wall pellitory (Parietaria) pollen, and grass pollen, 
Sopo et al (2004) concluded that only SLIT with house dust 
mite resulted in low to modest clinical beneﬁ  t in children 
with mild to moderate persistent asthma sensitized to this 
allergen. However, a different systematic review of 25 
studies concluded that SLIT had a modest beneﬁ  cial effect 
on asthma in terms of severity reduction (Calamita et al 
2006). Another study showed that children with hay fever 
to grass pollen who were treated with SLIT for 3 years had 
improved allergic rhinitis symptoms and reduced develop-
ment of seasonal asthma compared with children treated 
with standard symptomatic therapy (Novembre et al 2004). 
These preliminary results with SLIT for asthma treatment 
and prevention are promising; however, additional studies 
are needed on effective dose, treatment schedules, and dura-
tion of treatment with a speciﬁ  c allergy extract in different 
patient populations (Cox et al 2006).
Rush immunotherapy (RIT) is a procedure that enables 
rapid desensitization of allergic patients through repeated 
injections of allergenic extract over a short time period (Cox 
2006). Using this technique, the therapeutic maintenance 
dose can be achieved in as little as 1–3 days compared with 
3–6 months using conventional immunotherapy (Cox 2006). 
RIT has demonstrated efﬁ  cacy for several inhalant allergens, 
including dust mite (Kohno et al 1998), pollen (Movérare 
et al 2001), and mold (Horst et al 1990), although the high 
incidence of systemic reactions reported with RIT has lim-
ited its widespread use (Nelson 2007). In a study evaluating 
the effect of omalizumab treatment before initiating RIT on 
systemic reactions in patients with ragweed allergic rhinitis, 
fewer and less severe adverse events, including anaphylactic 
reactions, were observed with omalizumab pretreatment 
compared with RIT alone (Casale et al 2006). Further stud-
ies are needed to determine the optimal timing and dosing 
of omalizumab pretreatment in RIT protocols in different 
patient populations, including those with allergic asthma; 
however, the results from these studies suggest that RIT may 
hold promise in the future as a convenient immunotherapy 
option in allergic patients.
Biologic modiﬁ  ers
Tumor necrosis factor-alpha (TNF-α) is an inﬂ  ammatory 
cytokine produced by mast cells and found in the airways 
of patients with asthma (Rouhani et al 2005). Several small 
pilot studies suggest a possible role for blocking the effects 
of TNF-α in patients with severe, refractory asthma. The 
TNF-α antagonist, etanercept (Enbrel®; Immunex Corpo-
ration, Thousand Oaks, CA, USA), administered 25 mg 
subcutaneously twice weekly for 2 weeks, was evaluated in 
a randomized, placebo-controlled trial of patients with mild 
to moderate allergic asthma (n = 26) (Rouhani et al 2005). 
No appreciable clinical effect on measures of airway hyper-
responsiveness was demonstrated, and the trial was stopped 
early because one patient developed transient left-sided 
hemiplegia. In contrast, a placebo-controlled crossover study 
of patients with refractory asthma (n = 10) demonstrated that 
a twice-weekly course of etanercept 25 mg for 10 weeks was 
signiﬁ  cantly more effective than placebo in improvement in 
pulmonary function, asthma symptoms, and quality of life 
(Berry et al 2006). The humanized monoclonal antibody 
against TNF-α, inﬂ  iximab (Remicade®; Centocor, Malvern, 
PA, USA), was evaluated in a placebo-controlled trial of 
patients with moderately severe asthma (n = 38) (Erin et al 
2006). Inﬂ  iximab was administered as a 5-mg/kg intravenous 
infusion at weeks 0, 2, and 6. No signiﬁ  cant differences were 
observed between inﬂ  iximab and placebo in the change from 
baseline for morning PEF (primary endpoint). However, 
inﬂ  iximab treatment resulted in signiﬁ  cantly greater improve-
ments in the diurnal variation in PEF and reduced rates of 
exacerbations compared with placebo. These preliminary 
ﬁ  ndings suggest that larger trials are needed to conﬁ  rm the 
efﬁ  cacy of therapies directed against TNF-α.
Tacrolimus is a calcineurin inhibitor used orally as an 
immunosuppressive agent in organ transplantation (Prograf ®; 
Astellas Pharma US, Inc., Deerﬁ  eld, IL, USA) and topically 
(Protopic®; Astellas) in dermatologic conditions, such as 
psoriasis. The putative mechanism of action of tacrolimus in 
asthma is inhibition of type 2 T helper (Th2) cytokines and 
subsequent improvement in airway inﬂ  ammation (Matsuo 
et al 2001; Saeki et al 2004). A phase 2 trial of aerosolized 
tacrolimus in patients with asthma recently has been com-
pleted (ClinicalTrials.gov 2007d), but the results are not yet 
published.
Anti–interleukin-5 (IL-5) is another biologic modiﬁ  er 
under investigation in clinical trials. Mepolizumab is one Therapeutics and Clinical Risk Management 2008:4(2) 375
New approaches to managing asthma: a US perspective
monoclonal antibody against IL-5 that reduces eosinophils 
in the airways and periphery (Büttner et al 2003; Menzies-
Gow et al 2003), but a small, phase 1 trial (n = 24) failed 
to show a salient effect on airway hyper-responsiveness or 
allergen-induced bronchoconstriction in patients with mild 
allergic asthma (Leckie et al 2000). In a small, dose-rang-
ing study (n = 26), another monoclonal anti–IL-5 antibody 
(SCH55700) produced modest improvements in lung func-
tion in patients with severe asthma receiving high-dose ICS 
or oral corticosteroid therapy, but no change in other clinical 
endpoints versus placebo (Kips et al 2003). Determination 
of a possible role of antibodies directed against IL-5 awaits 
the results of further clinical trials.
Pharmacogenetics
In the future, pharmacogenetics may offer the opportunity 
to individualize asthma treatment based on associations 
between a particular genetic polymorphism and a predicted 
response to treatment (Wechsler 2006). Some pharmaco-
genetic studies have suggested that a homozygous arginine 
(Arg) genotype at amino acid position 16 of the β2-adren-
ergic receptor is associated with worsening asthma clinical 
outcomes in patients receiving the SABA albuterol (Taylor 
et al 2000; Israel et al 2000; Israel et al 2004) or the LABA 
salmeterol (Weschsler et al 2006). However, studies with 
LABAs show conflicting results (Dorinsky et al 2004; 
Bleecker et al 2006; Hancox et al 1998; Bleecker et al 2007; 
Goldman et al 2007). For example, two studies with the larg-
est homozygous Arg population to date (Arg/Arg, n = 430) 
demonstrated that genotype had no effect on the percentage 
of patients experiencing severe exacerbations or other clinical 
outcomes in response to the LABA FM when administered 
with the ICS BUD (Bleecker et al 2007). Based on these 
data, a homozygous Arg/Arg at amino acid position 16 of 
the β2-adrenergic receptor does not appear to affect treatment 
response to LABAs.
Other pharmacogenetic variations have been identiﬁ  ed. 
For example, studies have suggested that the transcription fac-
tor T-bet gene (TBX21) may be involved in the effect of ICS 
therapy on airway responsiveness in asthma (Tantisira et al 
2004; Raby et al 2006). Heterogenetic response to treatment 
with LTMs has been reported, which may be attributable 
to polymorphisms in genes that encode proteins in the LT 
pathway (Lima et al 2006; Lima 2007). For example, one 
study showed that response to treatment with montelukast 
may be inﬂ  uenced by particular polymorphisms in the cys-
teinyl leukotriene receptor 2, CYSLTR2, and arachidonate 
5-lipoxygenase, ALOX5, genes (Klotsman et al 2007). 
Additionally, some pharmacogenetic studies on asthma have 
demonstrated that polymorphisms in the prostanoid receptor 
genes PTGER2, PTGER3, PTGER4, PTGIR, and TBXA2R 
inﬂ  uence the pathogenesis of aspirin-intolerant asthma (Kim 
et al 2007).
Asthma is a variable disease with individual variation in 
symptoms and treatment responses. Although none of the 
genotypes in isolation explain the degree of patient variability 
in drug response (NAEPP 2007), future pharmacogenetic 
studies may identify additional genetic polymorphisms that 
affect individual treatment response and further elucidate the 
mechanisms involved in the genetic response to treatment. 
Pharmacogenetics may be used in the future to predict a 
patient’s response to treatment based on a patient’s genotype 
and allow for individualized treatment (Wechsler 2006; 
NAEPP 2007).
Gene therapy
Gene-based vaccines may have a role in immunomodula-
tion for patients who have corticosteroid-resistant asthma 
or severe asthma requiring systemic corticosteroid therapy 
(Kolb et al 2006). It has been postulated that gene therapies 
targeting the Th2 cell pathway involved in chronic airway 
inﬂ  ammation may be beneﬁ  cial in the treatment of asthma 
(Kolb et al 2006; Wang et al 2007). Results from Hogan 
et al (1998) demonstrated suppression of the Th2 response to 
aerosolized ovalbumin in mice after gene transfer of IL-12, 
thus inhibiting allergic airways disease. Moreover, overex-
pression of IL-12 restored local antiviral immunity, which 
may be relevant in patients who have viral-induced exacer-
bations (Hogan et al 1998). Another study in mice showed 
that allergen-induced airway hyperresponsiveness was 
signiﬁ  cantly inhibited by gene transfer of IFN-γ (Dow et al 
1999). In addition, a study by Mathieu et al (1999) suggested 
a potential role for gene therapy in corticosteroid-resistant 
asthma. In vitro gene transfer of the glucocorticocoid recep-
tor gene repressed nuclear factor-κB activities even without 
exogenous corticosteroids; thus, delivery of this gene may 
restore corticosteroid sensitivity in corticosteroid-resistant 
patients (Mathieu et al 1999).
Conclusion
Current treatment strategies approach asthma as a relatively 
homogeneous disease, addressing inflammation, bron-
choconstriction, and airway hyper-responsiveness using 
corticosteroids, SABAS, LABAS, LTMs, and other pharma-
cologic agents. Although signiﬁ  cant inroads to better patient 
outcomes have been achieved using currently available Therapeutics and Clinical Risk Management 2008:4(2) 376
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treatments, barriers to effective asthma control continue to 
exist, in part because of variability in treatment response and 
issues with treatment adherence.
The most recent asthma management guidelines, put 
forth by the NAEPP and GINA in 2007, provide updated 
recommendations in an effort to optimize asthma treatment 
and standardize approaches to diagnosis and assessment, all 
while retaining a focus on the individual. Recommendations 
include an initial evaluation of asthma severity followed 
by continued monitoring of asthma control at follow-up 
visits, factoring in the element of treatment responsiveness. 
In addition, the guidelines outline a step-wise approach to 
managing asthma, providing treatment recommendations for 
each step based on the most recent efﬁ  cacy and tolerability 
data. These recommendations are meant to assist clinicians in 
making treatment decisions; however, health care providers 
also must consider a variety of additional factors, including 
the patient’s asthma history and the likelihood of a patient 
to adhere to a particular treatment.
The goal of many newly available or emerging treatment 
approaches has been to provide effective, safe, and simple 
treatment options for patients with asthma. Other emerging 
treatments combine existing agents that have unique and 
complementary anti-inflammatory and bronchodilatory 
actions, such as the combination of FP/SAL administered via 
HFA pMDI and BUD/FM administered via DPI. BUD/FM 
has demonstrated a fast onset of action and effectiveness as 
maintenance and reliever therapy. This approach allows ther-
apy to be tailored to an individual’s changing needs. BUD/
FM as maintenance and reliever therapy is currently only 
available outside of the US. Other ICS/LABA combination 
therapies that are in development and offer promise include 
the combinations of ciclesonide/FM, mometasone/FM, and 
mometasone/indacaterol, all of which have rapidly acting 
LABAs. The monoclonal antibody therapy omalizumab, 
which is recommended in combination with high-dose ICS 
plus LABA by the recent NAEPP and GINA guidelines, 
offers a unique approach to treating patients with severe 
allergic asthma that is not controlled with high-dose ICS 
plus LABA. The novel immunotherapy anti–TNF-α anti-
body etanercept also is being investigated for the treatment 
of patients with severe asthma.
The variety of existing and emerging treatment options 
that address multiple facets of asthma offer promise for 
reducing the substantial health care and economic burden 
of asthma. In the near future, the development of more spe-
cialized diagnostic tests and the use of more individualized 
approaches to asthma management will be critical for further 
improving asthma outcomes. Research is currently underway 
to better understand the causes of inter- and intra-patient 
variability in treatment response, focusing on factors, such 
as obesity, genetic predisposition, and gene-environment 
interactions. Identiﬁ  cation of risk factors that contribute to 
differential response to treatment will aid clinicians in select-
ing the optimal treatments for their patients.
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